Skip to main content

Advertisement

ADVERTISEMENT

News

News
12/20/2023

University College London press release

University College London press relea...
A vest that can map the electrical activity of the heart in fine detail could potentially be used to better identify people at high risk of sudden cardiac death, suggests a new study led by UCL (University College London) researchers
A vest that can map the electrical activity of the heart in fine detail could potentially be used to better identify people at high risk of sudden cardiac death, suggests a new study led by UCL (University College London) researchers
A vest that can map the...
12/20/2023
EP Lab Digest
News
12/20/2023

Ajax Health Press Release 

Ajax Health Press Release 
Cortex's fully integrated solution will include advanced diagnostic and therapeutic pulsed field ablation catheters supported by innovative mapping technology.
Cortex's fully integrated solution will include advanced diagnostic and therapeutic pulsed field ablation catheters supported by innovative mapping technology.
Cortex's fully integrated...
12/20/2023
EP Lab Digest

Advertisement

News
12/20/2023

Pulse Biosciences Press Release 

Pulse Biosciences Press Release  ...
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation
Company’s proprietary system...
12/20/2023
EP Lab Digest
News
12/19/2023

Elutia Press Release 

Elutia Press Release 
SILVER SPRING, Md., Dec. 18, 2023 -- Elutia Inc. (Nasdaq: ELUT) today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its next-generation drug-eluting biomatrix product,...
SILVER SPRING, Md., Dec. 18, 2023 -- Elutia Inc. (Nasdaq: ELUT) today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its next-generation drug-eluting biomatrix product,...
SILVER SPRING, Md., Dec. 18,...
12/19/2023
EP Lab Digest
News
12/18/2023

LUMA Vision press release

LUMA Vision press release
LUMA Vision, developer of a novel four-dimensional (4D) cardiac imaging and navigation platform, today announced a total of $22 million in new financing for the company.
LUMA Vision, developer of a novel four-dimensional (4D) cardiac imaging and navigation platform, today announced a total of $22 million in new financing for the company.
LUMA Vision, developer of a...
12/18/2023
EP Lab Digest

Advertisement

News
12/14/2023

Biosense Webster Press Release 

Biosense Webster Press Release  ...
Study will evaluate investigational Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter potential to deliver safe and effective radiofrequency (RF) and pulsed field ablation (PFA)
Study will evaluate investigational Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter potential to deliver safe and effective radiofrequency (RF) and pulsed field ablation (PFA)
Study will evaluate...
12/14/2023
EP Lab Digest
News
12/14/2023

Medtronic Press Release 

Medtronic Press Release 
Safe, efficient, and effective treatment for both paroxysmal and persistent atrial fibrillation
Safe, efficient, and effective treatment for both paroxysmal and persistent atrial fibrillation
Safe, efficient, and effective...
12/14/2023
EP Lab Digest
News
12/14/2023

Lucem Health Press Release 

Lucem Health Press Release 
Groundbreaking Solution Identifies Undiagnosed AFib and Speeds Treatments Proven to Prevent Strokes
Groundbreaking Solution Identifies Undiagnosed AFib and Speeds Treatments Proven to Prevent Strokes
Groundbreaking Solution...
12/14/2023
EP Lab Digest

Advertisement

News
12/13/2023

Acesion Pharma Press Release 

Acesion Pharma Press Release 
AP30663 achieved proof of mechanism with first-in-class SK channel inhibition compound in atrial fibrillation – primary endpoint met: 99.9% probability of superiority over placebo AP31969, a novel compound being developed for sinus rhythm...
AP30663 achieved proof of mechanism with first-in-class SK channel inhibition compound in atrial fibrillation – primary endpoint met: 99.9% probability of superiority over placebo AP31969, a novel compound being developed for sinus rhythm...
AP30663 achieved proof of...
12/13/2023
EP Lab Digest
News
12/13/2023

StopAfib.org Press Release 

StopAfib.org Press Release 
DALLAS, Dec. 13, 2023 /PRNewswire/ -- StopAfib.org applauds the American College of Cardiology (ACC), American Heart Association (AHA), American College of Clinical Pharmacy (ACCP), and Heart Rhythm Society (HRS) for the newly released 2023...
DALLAS, Dec. 13, 2023 /PRNewswire/ -- StopAfib.org applauds the American College of Cardiology (ACC), American Heart Association (AHA), American College of Clinical Pharmacy (ACCP), and Heart Rhythm Society (HRS) for the newly released 2023...
DALLAS, Dec. 13, 2023...
12/13/2023
EP Lab Digest

Advertisement